Company intelligence
HLB Group
Global Bio Pharmaceutical Leader, HLB
About HLB Group
Guided by our philosophy, “Human Life Better,” HLB continues to expand its capabilities across biotechnology, pharmaceuticals, healthcare, distribution, and other industries. Through continuous innovation, strategic partnerships, and the integration of diverse businesses and technologies, HLB seeks to create sustainable growth and new value that can improve lives around the world. With Innovation, Connection, and Expansion at the core of our identity, HLB will continue to explore new possibilities and create lasting value that contributes to a better human life.
Verified activity
Signals from HLB Group
5 published signals
Presence & Recognition
HLB Group concluded its participation in Vitafoods Asia 2026 in Bangkok, introducing its proprietary antioxidant enzyme ingredient SODyZYM and engaging with approximately 30–40 global companies.
Reported by HLB Group
Customers & Market
HLB Group secured repeat orders in Taiwan and Thailand while supplying SODyZYM to customers in the United States and Brazil.
Reported by HLB Group
Customers & Market
HLB Group is targeting Vietnam and Indonesia as new strategic markets in Asia.
Reported by HLB Group
Partnerships
HLB Group signed an MOU with NEXEL to collaborate on organoid-based alternative testing and nonclinical research services.
Reported by HLB Group
Research & Knowledge
HLB Group's U.S.-based subsidiary Immunomic Therapeutics, Inc., has been featured in an invited review published in Allergology International highlighting its proprietary UNITE® immunotherapy platform.
Reported by HLB Group